QuickMIC® GN02 Gram-negative AST for highly resistant pathogens
QuickMIC® GN02 is designed to strengthen your lab's response to difficult-to-treat Gram-negative infections by providing rapid, reliable and precise MIC results.
- MIC results directly from positive blood cultures in 2–4 hours
- Broader antibiotic coverage including cefiderocol
- Designed for today's resistance challenges
Antibiotic coverage
Designed for today’s antimicrobial resistance challenges
QuickMIC® GN02 builds on the proven QuickMIC technology, combining rapid, precise MIC results with antibiotic coverage including cefiderocol for highly resistant Gram-negative pathogens.
Broader coverage for todays
Gram-negative
challenges
When treatment options narrow
For highly resistant Gram-negative infections, the treatment landscape can narrow quickly. As resistance limits the effectiveness of commonly used antibiotics, clinicians may need to rely on a smaller number of treatment options, including newer or more specialised therapies. Knowing which options remain effective becomes increasingly important.
Reliable AST matters more – and so does antibiotic coverage
As resistance increases, having relevant antibiotics represented in the AST panel becomes increasingly important. For difficult-to-treat Gram-negative infections, appropriate antibiotic coverage provides susceptibility information across relevant treatment options, helping inform targeted treatment decisions.
Cefiderocol: a critical treatment, a testing challenge
Cefiderocol is an important last-resort treatment option for resistant Gram-negative infections. Knowing when it is likely to be effective — and when it is not — supports appropriate use and helps preserve critical treatment options. QuickMIC® GN02 enables cefiderocol susceptibility testing within the established QuickMIC workflow, without a separate iron-depleted media workflow.
The three clocks
Different timelines. A shared goal: the right treatment, sooner.
Infection clock
Serious bloodstream infections can progress rapidly, increasing the importance of timely treatment decisions.
Resistance clock
Empirical therapy becomes less reliable as local resistance increases.
Laboratory clock
Faster results enable faster decisions. QuickMIC® delivers MIC results in 2–4 hours from positive blood cultures.
Expanded rapid AST
QuickMIC® GN02 combines antibiotic coverage for highly resistant Gram-negative pathogens, including cefiderocol and other clinically relevant antibiotics, with precise MIC results directly from positive blood cultures in 2–4 hours.
- Broader antibiotic coverage including cefiderocol
- MIC results directly from positive blood cultures in 2–4 hours
- Supports targeted treatment and antimicrobial stewardship
